Wednesday, December 19, 2012

Stevia Stock Breaking News; Sunwin Stevia (OTCQB: SUWN) Sees Health Canada Approval of Stevia for Use in Food and Beverages Opening a New Large Market

QUFU, China - December 19, 2012 (Investorideas.com Newswire) Sunwin Stevia International, Inc. "Sunwin" (OTCQB:SUWN), one of the top global providers of high quality stevia extracts including Rebaudioside A 98, announced today that it sees Health Canada's approval for the use of stevia in food and beverages on November 30, 2012 opening a new large market for Sunwin Stevia. Prior to this approval, stevia was available in Canada only within natural health product applications.

Stevia is a natural zero calorie sweetener and can be used by diabetics. This approval means that consumers across Canada will soon be able to enjoy a similar range of stevia sweetened products to those already available in other markets where stevia has already received government approval for use in the food and beverage industry such as the United States and the European Union.
Sunwin Stevia has been working with a number of Canadian companies seeking to incorporate stevia in the product development process in anticipation of Health Canada's approval. There has been a significant increase in interest potential projects using Sunwin's stevia over the last year since Health Canada has made steps forward in approving stevia for use within food and beverages. Sunwin Stevia believes that while numerous food and beverage companies have been proactively working with the ingredient prior to this notice, Health Canada's approval will provide the confidence required for many of these organizations to invest further in the R&D and formulation work to quickly begin to introduce stevia based products to the Canadian marketplace.
Ms. Dongdong Lin, CEO of Sunwin Stevia International, stated, "Since 1996, Sunwin Stevia has been investing in stevia farming and production to be in the forefront of this industry. This approval in Canada is another strong step forward for the stevia industry as it opens another large consumer market for food and beverages. We have invested a great deal of capital in positioning Sunwin Stevia as a global leader with a technologically advanced processing capacity to service this growing industry and we anticipate further sustained growth for stevia in the food and beverage industry as more countries open their markets for this healthy great tasting sweetener."
About Sunwin Stevia International, Inc.
Sunwin Stevia International, Inc. engages in the areas of zero calorie, all natural sweeteners (Sunwin Stevia™ Extracts). As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. For more info about Sunwin, please visit http://www.sunwininternational.com.
Safe Harbor Statement
Sunwin Stevia International, Inc. is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects") may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our ability to return our revenues to historical levels, our dependence on continued market acceptance of our products, competition, our ability to control our raw material costs, risks associated with operating in China, and other risk factors impacting our company, some of which may be beyond our control. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the fiscal year ended April 30, 2012.
Contact:
Dore Perler
U.S. Representative
954-232-5363
ir@sunwininternational.com
Published at Investorideas.com Newswire
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com is compensated by China Direct on behalf of SUWN, averaging four thousand per week for news publication, dissemination and profile on Investorideas.com, its affiliate news and email sites http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Tuesday, December 18, 2012

Stevia Stock Alert; Sunwin Stevia (OTCQB: SUWN) 2014 Revenue to Reach $18 Million

Point Roberts, WA - December 18, 2012 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors issues a trading alert and news for agriculture stevia stock, Sunwin Stevia International, Inc. (OTCQB:SUWN). The stock is up in morning trading, currently at $0.29, up 0.0420 or 16.94%as of 9:30AM EST.

The Company reported yesterday it expects sales and operating income to improve in fiscal 2014 which begins on May 1, 2013 as worldwide demand for stevia is forecasted to rise and supply chain pricing pressures begin to ease. Sunwin Stevia sees fiscal 2014 revenue reaching $18 million in annual sales with $2 million in net operating income.
Full news: http://www.investorideas.com/ CO/SUWN /news/2012/12171.asp
About Sunwin Stevia International, Inc.
Sunwin Stevia International, Inc. engages in the areas of zero calorie, all natural sweeteners (Sunwin Stevia™ Extracts). As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. For more info about Sunwin, please visit http://www.sunwininternational.com
WILD Flavors Gmbh is the worldwide distribution partner and developer of Sunwin Stevia™ sweeteners using Sunwin Stevia™ extracts.
WILD Flavors GmbH, based in Zug, Switzerland, is one of the world's leading privately-owned manufacturers of natural ingredients for the food and beverage industry. WILD Flavors provides specific flavors, colors, and ingredients as well as innovative and great tasting concepts through application expertise and technological advancements. www.wildflavors.com or www.wild.de.
Research more Agriculture and stevia stocks at Investorideas.com ( NASDAQ:SANW), (NYSE:INGR), (LSE:PURE.L), (OTC:STVF)
http://www.investorideas.com/MSS/Arg_Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
More Sunwin info at Investorideas.com http://www.investorideas.com/CO/SUWN/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com is compensated by China Direct on behalf of SUWN, averaging four thousand per week for news publication, dissemination and profile on Investorideas.com, its affiliate news and email sites
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Monday, December 17, 2012

Investing in Junior Gold and Silver Mining Stocks; Q&A Interview with Andrew Portmann, Asset Manager and Director of THE TIMELESS PRECIOUS METAL FUND

New York, NY, Point Roberts, WA - December 17, 2012 (Investorideas.com Mining stocks newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors including mining stocks features an exclusive Q&A interview with Andrew Portmann, Asset Manager and Director of THE TIMELESS PRECIOUS METAL FUND.

Q: Investorideas.com
Your fund invests in the juniors in the mining sector, which differentiates it from many of the larger funds; can you tell investors why your fund has chosen to focus on this particular group of stocks?
A: Andrew Portmann, Asset Manager and Director
Our focus is directed to the juniors in the gold and silver mining sector. Peter Zihlmannn, who launched the fund in 2004, had prior to that date managed discretionary accounts in this sector. Consequently we have a wealth of knowledge and many years of experience. Therefore we know a huge range of people and projects in the junior precious mining space. This is a great advantage while filtering and analyzing the huge number of junior miners out there.
We believe that exploration companies making the transition to producers create the most value to investors. Now clearly the selection of companies is the most difficult task, knowing that many explorers never make it. It is here where our mentioned expertise helps us avoiding the black sheep in the industry.
We invest in junior miners all over the world. Having a Malta based investment fund allows us to buy attractive companies at any global stock exchange, being Australia, UK or Canada.
Q: Investorideas.com
Can you give investors some insight as to the performance of juniors in relationship to actual gold and silver prices and if you think this trend will continue? And in that light can you give examples of the performance of some of the companies in your fund?
A: Andrew Portmann, Asset Manager and Director
This year has not been great for investors in precious metals, nor the mining stocks. Generally speaking the miners have slightly underperformed bullion. Looking at the gold miners in more detail one sees huge variance in the stock performance. Companies with good progress, growth in resources, production and cash-flow have been rewarded. Good examples would be First Majestic Corp. and SilverCrest Mines ( TSX.V: SVL ) ( NYSE MKT: SVLC ) in the silver space and Beadell Resources and Rio Alto Mining in gold. All four companies have been successful in turning projects into production within a couple of years.
The underperformance of gold and silver mining equity in relation to metal prices since 2007 is substantial. The equity / gold ratio has never over the past 30 years been so low. Valuations of the junior gold and silver mines in regards to their resources and future production are – based on current precious metals prices – on a historical low level. Senior mining companies are increasingly looking at takeovers at these bargain prices. We are convinced that M&A activities will increase over the next couple of months. A recent example is the merger of Keegan Resources with PMI Gold or First Majestic buying Orko Silver.
Q: Investorideas.com
What are your thoughts on gold and silver prices moving into the New Year?
A: Andrew Portmann, Asset Manager and Director
The US fiscal cliff has been the dominating theme lately. The worry is that about $600 billion worth of tax and spending cuts will start hitting the US economy in 2013 and could send the US economy into recession. This issue will be solved, as we do not believe the new government and the president will allow the economy to slide back into recession. Gold will profit as well, as the Fed will support the financial markets, the government and the economy with ample liquidity. So, in the end it is the ongoing macro-economic issues supporting the gold and silver price. While the Fed, the ECB and the BOJ are gradually printing more and more money and devaluing their currencies, gold will appreciate. We have no doubt that silver will follow gold's path up.
In the wake of higher gold prices the mining stocks should outperform both global equity markets as well as gold bullion.
Q: Investorideas.com
Can you tell investors some of the top factors in your research/decision making process when evaluating a junior mining company?
A: Andrew Portmann, Asset Manager and Director
In the junior mining sector it is important to be a stock picker. For us this means looking very precisely at the project/s and the management of the company. Having a quality management team in place is the basis for a successful company. The question for us is, can they advance the project toward a mine and will they be able to raise the needed capital to get there? Juniors currently are having a very difficult time getting funding for exploration and early stage projects. Consequently selecting companies with sufficient cash in the bank is essential. Everyone will tell you: “Grade is king.” But as we can see from mines in Nevada this is only half of the truth. It is the relationship between grade, tons, depth and more that show us, if the metal can be extracted economically. We see ourselves as value investors, which mean we are looking for the best value available. If we believe a resource can be turned into production within four years and you pay $50 for ounce; well then this value proposition.
<Q: Investorideas.com
Typically what kind of investors is attracted to your fund and what are the process/criteria for an interested new investor?
<A: Andrew Portmann, Asset Manager and Director
We offer a product that invests in junior precious metals mining companies only. There are not too many around like us that can choose from the most promising juniors on global bases. Investors believe that the historical low valuations provide a good opportunity to invest in gold equities and that the junior offer superior return to junior companies in the next price move. Subscription of our Malta based SICAV fund can be done through your bank or directly, with no extra charge, at the fund's custodian bank. The fund offers weekly liquidity with no waiting period.
THE TIMELESS PRECIOUS METAL FUND (http://www.timeless-funds.com/en/timeless-precious-metal-invest-philosophy) invests in listed mining companies of medium or small market capitalisation which have to fulfill the following criteria:
  • Companies that are in production on the one hand, and have a high potential of substituting exhausted resource bases, and at the same time, of adding new reserves.
  • Companies that are set to go into production and that have considerable exploration prospects
  • Companies that concentrate on the exploration for precious metals in commodity rich regions that already have a substantial resource.
  • We consider the experience and integrity of the mining company's management as another important investment criterion.
We believe that medium sized mining companies offer more growth potential in the long-term than major mining companies as it is easier for them to grow their resource base.
Shares of medium sized mining companies are more volatile than big cap mining stocks and are best suited for long-term investors. We also believe that mining companies are extremely undervalued at this time in relation to gold and silver and that, for this very reason, they offer an outstanding capital gain potential.
<Andrew Portmann, Asset Manager and Director Bio and contact info
Director, domiciled in Zurich, Switzerland
Over 15 years of experience in the banking and finance industry. He holds a BBA and is a certified international investment analyst (CIIA). Before joining Peter Zihlmann he was co-manager of two precious metals hedge funds at Incentive
Asset Management.
Email contact: andrew.portmann@pzim.ch
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for free stock news and trading alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: SVL is a showcase company on Investorideas.com http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source Investorideas.com 800 665 0411

Stevia Stock Investor Alert: Sunwin Stevia (OTCQB:SUWN) Expects Sales to reach $18 million in Fiscal 2014 with $2 million in Net Operating Income

QUFU, China - December 17, 2012 (Investorideas.com Newswire) Sunwin Stevia International, Inc. "Sunwin" (OTCQB:SUWN), one of the top global providers of high quality stevia extracts including Rebaudioside A 98, announced today that the company expects sales and operating income to improve in fiscal 2014 which begins on May 1, 2013 as worldwide demand for stevia is forecasted to rise and supply chain pricing pressures begin to ease. Sunwin Stevia sees fiscal 2014 revenue reaching $18 million in annual sales with $2 million in net operating income.

Over the past two years, Sunwin Stevia has been undergoing major changes to solidify a position as one of the global leaders in the production of high quality stevia extracts through a significant investment of capital in research and development as well as a substantial upgrade of its production facilities. During this past year there has been a substantial decline in the overall price of higher grades of stevia, mainly due to a major supplier in financial difficulty liquidating inventories as well as slower than expected adoption rates in the U.S. While this has resulted in declining margins for the entire industry and a significant decline in revenue at Sunwin Stevia thus far in fiscal 2013, management believes these pressures are beginning to abate and the expansion of stevia in the E.U. as well as increased use in the U.S. will lead to an improving environment in calendar 2013 and beyond. Sunwin Stevia’s investment in technology will also help to lower its production costs to help improve overall margins when sales are expected resume a strong growth track.
Management believes Sunwin Stevia is well positioned to take advantage of industry trends that will result in substantially increased usage of stevia in the coming years in numerous food products including beverages, candies, baked goods, sweeteners, sauces and seasonings, and snacks. Datamonitor in a 2012 Food Navigator article estimates stevia product launches in North America to reach approximately 230 products in 2012 up from a few dozen launches per year in the 2006 to 2008 timeframe. Zenith International also estimates worldwide sales of stevia extract which reached 3,500 tons in 2010 with an overall market value of $285 million will reach as much as 11,000 tons by 2014.
More than 40 countries have either approved stevia for use in food products or are in the final stages of approval. Combined, it is estimated that more than 1,000 products worldwide now contain stevia, ranging from beverages to energy bars.
"We sell our low-grade and high-grade stevia extract directly to a number of international and domestic customers, including food and beverage companies, food ingredient companies, and flavor houses. Additionally, we have partnered with distributors that resell Sunwin Stevia’s products in a number of markets across the globe”, commended by Ms. Dongdong Lin, CEO of Sunwin Stevia International. "We have been able to demonstrate our integrated supply chain capabilities which have resulted in partnerships with leaders in the industry and now, through our capital investment in improving production efficiencies and farming integration, we believe we are well positioned to benefit from the tremendous global growth opportunities for stevia in the years to come. We are confident that we have positioned Sunwin Stevia on a solid foundation to scale production capacity and target substantial growth in top and bottom line performance in the coming fiscal year."
About Sunwin Stevia International, Inc.
Sunwin Stevia International, Inc. (OTCQB: SUWN) engages in the areas of zero calorie, all natural sweeteners (Sunwin Stevia™ Extracts). As an industry leader in agricultural processing, Sunwin Stevia has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. For more info about Sunwin Stevia, please visit http://www.sunwininternational.com
Safe Harbor Statement
Sunwin Stevia International, Inc. is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects") may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations regarding demand for stevia, our revenues, net income and earnings our ability to increase stevia production capacity. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the fiscal year ended April 30, 2012.
Contact:

Dore Perler
U.S. Representative
954-232-5363
ir@sunwininternational.com
Published at Investorideas.com
Research more Agriculture and stevia stocks at Investorideas.com
http://www.investorideas.com/MSS/Arg_Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
More Sunwin info at Investorideas.com http://www.investorideas.com/CO/SUWN/
Download the IR App athttp://runningbullotc.com/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com is compensated by China Direct on behalf of SUWN, averaging four thousand per week for news publication, dissemination and profile on Invesotrideas.com , its affiliate news and email sites
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Thursday, December 13, 2012

WILD invested in stevia research and development and acquired shares in the stevia manufacturer Sunwin International (OTCQB:SUWN)

Point Roberts, WA - December 13, 2012 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors issues a news alert for agriculture stevia stock, Sunwin Stevia International, Inc. (OTCQB:SUWN) and WILD Flavors Gmbh , its worldwide distribution partner and developer of Sunwin Stevia™ sweeteners using Sunwin Stevia™ extracts .WILD Flavors GmbH, based in Zug, Switzerland, is one of the world's leading privately-owned manufacturers of natural ingredients for the food and beverage industry.
Investorideas.com Newswire
One year after the European Union granted approval for steviolglycosides to be marketed, WILD has noted positive interim results. The great-taste expert has worked with customers to create a number of stevia-sweetened products that have been market successes — everything from beverages to candies.
Stevia's great potential is the two key properties it combines: it is derived from a natural source, and it has no calories. These features meant that anticipation about what stevia could do was quite high even before it received official marketing approval in Europe . Early on, WILD invested in stevia research and development and acquired shares in the stevia manufacturer Sunwin International. In doing so, the corporation acquired solid expertise in terms of applications in different finished products. "We were perfectly prepared for the large demand, and we managed to launch the first products very quickly in places like Scandinavia and central Europe . More and more food and beverage manufacturers in Germany as well have been asking us about stevia over the course of the past year. There is great interest throughout Europe," states Silke Ortmann, product manager of sweetener systems at WILD.
The main criterion: the taste
WILD has joined forces with manufacturers to create several different products with stevia, including near waters, tea beverages, carbonated soft drinks as well as hard caramels, chewing gums and chocolate products. WILD's portfolio features different kinds of reb-A, and depending on the customer specification and market demand, the company can create low- or no-calorie products with compelling sensory profiles. Having an outstanding taste is critical if a food or beverage is to be a long-term success. "This is why we developed our 'Taste Optimization Technology,' which offsets the licorice-like and somewhat bitter aftertaste of stevia. We make it available to manufacturers in direct conjunction with premium stevia extracts," Silke Ortmann says. "Our customers very much appreciate this turnkey solution."

Another sweetener from WILD's portfolio also offers ways to round out the flavor profile of a finished product: Fruit Up® is a natural fruit sweetener which can be effectively combined with stevia. Fruit Up® is derived exclusively from fruit and is appealing to manufacturers, both because of its sensory profile and because of the labeling options it creates.
Developing market opportunities
In WILD's product portfolio to date, Sunwin Stevia™ was only used as an ingredient in foods and beverages. In the meantime, however, the company has also developed a stevia table-top sweetener. This allows manufacturers to distribute stevia as a finished product, thus developing further sales potential and market opportunities for the sweetener.
WILD produces the table-top sweetener in powdered form. It contains 60% rebaudioside A, which is known for its particularly good sensory properties, and can be processed in different forms such as tablets, powder or cubes. "We not only offer our customers Sunwin Stevia™, we also provide additional consultation in terms of packaging options, marketing strategies and labeling issues," Silke Ortmann says.
About WILD Flavors GmbH
WILD Flavors GmbH is headquartered in Zug , Switzerland , and is one of the world’s leading suppliers of natural ingredients to the food and beverage industry. The company’s management offices and production sites are located at Rudolf WILD GmbH & Co. KG in Eppelheim ( Germany ) as well as in Erlanger ( Kentucky , USA ). Eight further production locations in Europe, USA , Canada , China , and Dubai are part of WILD Flavors GmbH as well.
The WILD Flavors product portfolio of natural-flavor ingredients includes full flavor and ingredient solutions for the food and beverage industry, known as flavor systems, as well as individual components such as flavors and extracts, natural colors, concentrates, sweetening systems, specialty ingredients and seasonings, including functional flavors and healthy ingredients, taste modifiers, and fermentation technologies. WILD Flavors' competence of global supply markets as well as technologically advanced production processes brings value to our customers on a daily basis. www.wild.de or www.wildflavors.com
News source: http://www.wild.de/wild/ opencms/en/service/ press_room/news/stevia_one_year.html
About Sunwin Stevia International, Inc.
Sunwin Stevia International, Inc. engages in the areas of zero calorie, all natural sweeteners (Sunwin Stevia™ Extracts). As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. For more info about Sunwin, please visit http://www.sunwininternational.com
Research more Agriculture and stevia stocks at Investorideas.com
http://www.investorideas.com/MSS/Arg_Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
More Sunwin info at Investorideas.com http://www.investorideas.com/CO/SUWN/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com is compensated by China Direct on behalf of SUWN, averaging four thousand two hundred per week for news publication, dissemination and profile on Investorideas.com, its affiliate news and email sites including ir app on Running Bull http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Wednesday, December 12, 2012

Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Announces Expansion of Compassionate-Use Program To Treat Hepatitis C Virus (HCV)

SAN DIEGO - December 12, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that a compassionate-use clinical program that provides HCV-infected individuals with access to the Hemopurifier� therapy, has been expanded to include individuals who experience a viral breakthrough during standard-of-care drug therapy.
Investorideas.com Newswire
The Aethlon Hemopurifier� is a first-in-class medical device that selectively targets the rapid clearance of HCV from the entire circulatory system to improve benefit, dosing, duration and tolerability of drug therapies. A virologic breakthrough occurs when infected individuals achieve undetectable HCV levels after drug therapy initiation, but then experience a rebound in HCV levels prior to completion of therapy. Researchers often attribute viral breakthroughs to the development of drug resistance or the emergence of HCV subtypes that are less sensitive to drug therapy.
"It is immensely disheartening when HCV-infected individuals initially respond but are then forced to discontinue their drug therapy as the result of a viral breakthrough," stated Aethlon Chairman and CEO, Jim Joyce. "Whether it be interferon-based or future all-antiviral drug strategies, there is an enduring opportunity for our Hemopurifier� to help individuals salvage benefit from their HCV drug regimen."
Aethlon previously disclosed that the compassionate-use program, which was approved by the Institutional Review Board at the Medanta Medicity Institute (Medicity), would allow individuals who previously failed or subsequently relapsed standard-of-care drug regimens with treatment access to the Aethlon Hemopurifier�. Individuals who fail drug therapy maintain detectable HCV levels throughout the course of drug therapy, whereas a treatment relapse is defined when HCV levels decrease and remain undetectable during treatment, but become detectable after cessation of therapy. The Medicity is a $360 million multi-specialty medical institute established to be a premier center for medical tourism in India. Additional details about the Medicity can be found online at www.medanta.org. Under the compassionate-use program, the Medicity is offering Hemopurifier� therapy to HCV-infected individuals that reside in India or travel from other regions and meet the inclusion/exclusion criteria that have been established for participation.

The Treatment Protocol
The Medicity is offering compassionate-use access to Hemopurifier� therapy on a minimum three-day treatment regimen with the option for patients to extend treatment to a maximum period of seven consecutive days. During each treatment day, Hemopurifier� therapy is administered for a duration of up to six-hours. In HCV-infected individuals who previously failed or subsequently relapsed drug therapy, the goal of Hemopurifier� therapy is to accelerate the early viral kinetic response to drug therapy without adding drug toxicity or interaction risks. More specifically, Hemopurifier� therapy targets to increase immediate and rapid virologic response rates, which correlate with high clinical cure rates. In viral breakthrough patients, the goal of Hemopurifier� therapy is to reset viral load to undetectable levels as a strategy to salvage the continuance and benefit of drug therapy.
Medicity is offering the three-day treatment regimen at $7,235.00 (USD), which includes Hemopurifier� therapy, physician and support fees, hospital lodging, catheter and other consumables. The cost for each treatment day beyond the minimum three-day regimen is $2,295.00. Pre-treatment consult and post treatment monitoring is charged at $200/day and includes transportation to and from hotel.
The Medicity has established the following inclusion and exclusion criteria for candidate patient consideration:
Inclusion Criteria
  • Males or females 18 years of age and older testing positive for any HCV genotype
  • Patients who initially responded to standard-of-care drug therapy, but have since suffered a virologic breakthrough
  • Patients who relapsed after completing a previous course of standard-of-care drug therapy
  • Null responders or patients who previously were unable to achieve > 2 log viral load reduction at month three of standard of care drug therapy
  • Candidate patients must be willing to submit to temporary vascular access catheterization
  • Ability to tolerate blood volume losses of up to 150 ml per week
  • Stable clinical condition, including stable hematocrit
  • Patients on ACE inhibitors must suspend ACE inhibitor administration for a minimum of six days prior to initiating therapy.
  • Karnofsky score ≥ 60
  • A more detailed list of inclusion criteria, including blood chemistry requirements will be provided to candidate patients who meet the above criteria
  • The subject must be informed of the investigational nature of this study and written informed consent obtained prior to enrollment in this study
Exclusion Criteria
  • Clinically significant infection, other than HCV, defined as any acute viral, bacterial, or fungal infection, which requires specific therapy (Anti-infectious therapy must have been completed at least 14-days before entry into study).
  • Co -infections with Hepatitis B virus and Human immunodeficiency virus ( HIV )
  • Received any investigational agent(s) within 28-days of entry into study
  • Any known pre-existing medical condition that could interfere with the subject's participation in the protocol, including serious psychiatric disorders, CNS trauma or active seizure disorders requiring medication, poorly controlled diabetes mellitus, significant cardiovascular dysfunction within the past 6 months (e.g., angina, congestive heart failure, recent myocardial infarction, severe hypotension, or significant arrhythmia)
  • Subjects with ECG showing clinically significant abnormalities
  • Need for frequent blood transfusions.
  • Recent History of bleeding or bleeding disorders requiring the restriction in use of anticoagulants during study treatments.
  • Active immunologically mediated disease (e.g., inflammatory bowel disease [Crohn's disease, ulcerative colitis], rheumatoid arthritis, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, autoimmune or inherited hemolytic anemia, scleroderma, severe psoriasis).
  • Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids or other immunoregulatory medications
  • Substance abuse, such as alcohol (~80 gm/day), IV drugs, and inhaled drugs (If the subject has a history of substance abuse, to be considered for inclusion into the protocol, the subject must have abstained from using the abused substance for at least 2 months. Subjects receiving methadone within the past year are also excluded.)
  • Any cancer requiring systemic chemotherapy
  • Any other condition that, in the opinion of the Principal Investigators, would make the subject unsuitable for enrollment, or could interfere with the subject participating in and completing the protocol
Individuals interested in the study are encouraged to contact:
Dr Puneet Sodhi
Mail ID: puneet.sodhi@Medanta.org
Contact No.: +91-9910002681
Jitendra Kumar Gupta
Mail ID: jitendra@qualtran.com
Contact No.: +91-9313365371
Information requests can also be sent directly to Aethlon Medical at: info@aethlonmedical.com
Current HCV Studies
Aethlon has previously reported data from a clinical program at the Medicity that is evaluating the capability of the Aethlon Hemopurifier� to accelerate HCV RNA depletion at the outset of standard of care peginterferon+ribavirin (PR) therapy. In this study, HCV-infected individuals are enrolled to receive up to three, six-hour Hemopurifier� treatments during the first three days of PR drug therapy. Aethlon recently reported that two HCV-infected patients who received Hemopurifier� therapy in combination with PR drug therapy achieved undetectable viral load at day-7, which is rarely reported in drug therapy alone.
The primary clinical endpoint of this study protocol has been to increase the incidence of rapid virologic response (RVR), defined as undetectable HCV RNA at day 30 of therapy. RVR represents the clinical endpoint that best predicts treatment cure, otherwise known as sustained virologic response (SVR), defined as undetectable HCV RNA 24-weeks after the completion of PR drug therapy. As a point of reference, the landmark IDEAL Study of 3,070 HCV genotype-1 patients documented that only10.35% (n=318/3070) of PR treated patients achieved a RVR. However, patients that achieved a RVR had SVR rates of 86.2% (n=274/318) versus SVR rates of 32.5% (n=897/2752) in non-RVR patients. While the incidence of undetectable HCV RNA at day-7 is not reported in the IDEAL study, the study did reveal that just 4.3% (n=131/3070) of patients achieved undetectable HCV RNA at day-14, which equated to a 91% (n=118/131) SVR rate.
To date, Aethlon has reported that Hemopurifier� therapy has been well tolerated and without device-related adverse events in the first ten treated patients. Of these ten patients, seven patients were infected with HCV genotype-1; two patients were infected with HCV genotype-3; and one patient was infected with HCV genotype-5. Aethlon previously reported undetectable HCV RNA in eight of the 10 treated patients. Of the two patients reported to have detectable HCV RNA, one had discontinued PR therapy as a result of a diabetes related condition. HCV RNA is undetectable in all patients (n=4) that have been monitored for 48 weeks since receiving Hemopurifier� therapy. Among the 10 treated patients, Aethlon reported that six genotype-1 patients received the three treatment Hemopurifier� protocol, which resulted in four (67%) patients achieving a RVR. The IDEAL study predicts it would normally require approximately 40 PR treated patients to achieve 4 RVR outcomes. Both patients who achieved undetectable HCV RNA at day-7 also achieved a RVR. Beyond the high likelihood of a SVR, genotype-1 patients that achieve a RVR also have the opportunity to reduce the duration of PR drug therapy from 48 weeks to 24 weeks.
Aethlon expects to report updated results, including new patient data from this study in the near future. The Company also disclosed it is presently incorporating new patient data within investigational device exemption (IDE) that is expected to be submitted to FDA by year-end in an effort to gain approval to initiate HCV clinical programs in the United States.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with DARPA that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com Newswire
More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/
Disclaimer: Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release. Aethlon Medical, Inc. is currently an annual news release client at Investorideas.com and compensates Investorideas.com $2425 quarterly to publish and distribute news with Investorideas and its syndication partners
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Tuesday, December 11, 2012

Stevia Stock Alert: Sunwin Stevia International, Inc. (OTCQB: SUWN) Gains New Coverage as Industry Ramps Up

POINT ROBERTS, WA - December 11, 2012 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors, issues a news and media alert for agriculture stevia stock, Sunwin Stevia International, Inc. (OTCQB:SUWN). Sunwin has gained momentum with food industry media and investment media as it ramps up for the anticipated global demand as new regulatory approvals increase markets.

Sunwin Stevia was featured in a SeekingAlpha.com in an article today entitled," Companies Gear Up As Health Canada Approves Stevia As Additive For Food And Beverage Use “. Author Glen S. Woods notes," Given the continued expansion of stevia globally, Sunwin may well be one of those small companies that may benefit shareholders with impressive stock gains if its success continues."
The Company was also featured in BakeryandSnacks.com November 30 th and FoodProductionDaily.com December 5 th. (see below)
Summary of Coverage:
Sunwin (OTCQB: SUWN) on SeekingAlpha.com - Companies Gear Up As Health Canada Approves Stevia As Additive For Food And Beverage Use
December 11, 2012 by: Glen S. Woods | includes: MNST, STVF.OB, SUWN.OB
http://seekingalpha.com/article/1056111-companies-gear-up-as-health-canada-approves-stevia-as-additive-for-food-and-beverage-use
Excerpt from article:
Sunwin Stevia International (SUWN.OB), based in Qufu, China, a vertically-integrated manufacturer of stevia products and traditional Chinese medicines, announced the installation of new high-tech production lines to expand its stevia production capacity to 1,300 metric tons, including 500 metric tons of high-grade stevioside Rebaudioside A (Reb A), and 500 metric tons of steviosin, a stevioside extract used by the pharmaceutical industry. Sunwin began its expansion project in April anticipating an improvement in demand for stevia as a healthy low calorie sweetener and is now poised to capitalize on the industry's upward trend. With Canada's approval of stevia, it becomes apparent that the company was correct as stevia continues to grow in worldwide acceptance. Sunwin's new stevioside extraction line uses a state-of-the-art crystallization process that substantially reduces the production time while increasing product yield leading to a substantial reduction in overall processing costs as utilization rates increase. Sunwin has begun trial production of its new lines and anticipates its added production capabilities to be fully operational in the first quarter of 2013.
In August Sunwin entered into a worldwide stevia distribution agreement with WILD Flavors, giving WILD a non-exclusive worldwide right as a distributor to market and resell all Sunwin stevia products. Sunwin is also developing 6 new formulations in conjunction with WILD with the goal of penetrating the $10.3 billion Chinese bakery market by marketing to manufacturers to develop private label products - a move that the company sees will bolster its domestic production base in China.
Sunwin, with a market cap of $45.1 million, has had an impressive 3-month run, up 30% to $0.27 per share, but still off its 52-week high of $0.35 per share. In the past week of trading, its volume has risen to an average of 41,000 shares traded daily. I like the aggressiveness of Sunwin, and its timing appears to be spot on, especially with Canada's announcement last week. Given the continued expansion of stevia globally, Sunwin may well be one of those small companies that may benefit shareholders with impressive stock gains if its success continues
Sunwin Stevia pours cash into production
FoodProductionDaily.com - December 5, 2012
Sunwin Stevia International has invested heavily in production capacity to support declared growth plans in China.
http://www.foodproductiondaily.com/Processing/Sunwin-Stevia-pours-cash-into-production
Sunwin to broaden stevia presence through Chinese private label bakery
By Kacey Culliney November 30 th- BakeryandSnacks.com
Sunwin Stevia International hopes to penetrate the Chinese bakery sector further by targeting the private label segment with a range of stevia formulations
http://www.bakeryandsnacks.com/Formulation/Sunwin-to-broaden-stevia-presence-through-Chinese-private-label-bakery
About Sunwin Stevia International, Inc.
Sunwin Stevia International, Inc. engages in the areas of zero calorie, all natural sweeteners (Sunwin Stevia™ Extracts). As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. For more info about Sunwin, please visit http://www.sunwininternational.com
Research more Agriculture and stevia stocks at Investorideas.com
http://www.investorideas.com/MSS/Arg_Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
More Sunwin info at Investorideas.com http://www.investorideas.com/CO/SUWN/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com is compensated by China Direct on behalf of SUWN, averaging four thousand two hundred per week for news publication, dissemination and profile on Invesotrideas.com , its affiliate news and email sites including ir app on Running Bull http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Monday, December 10, 2012

Stevia; A Solution in the Battle Against Diabetes and Obesity

POINT ROBERTS, WA - December 10, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research for independent investors issues a sector snapshot for stevia stocks/agriculture stocks and the role stevia may play in the potential battle against diabetes and obesity, as a natural replacement to sugar.

An article today in Theage.com noted "Stevia has been said, by many, to be the sweet solution to the sugar 'problem'. Native to Paraguay, the stevia plant is as much as 300 times sweeter than sugar, but has barely any effect on blood glucose levels and contains no calories.
It's pitched as the 'natural' alternative to artificial sweeteners and is the choice of US physicist and renowned sugar critic, Gary Taubes, who has said that by spiking our insulin levels, sugar, not fat, is responsible for the obesity epidemic and a slew of related illnesses."
Lauren Bandy, an Ingredients Research Analyst with Euromonitor International, recently said "Stevia offers food and beverage manufacturers a way to reduce the sugar content of their products in a more natural way. Health and wellness is a key trend in the food and beverage sector and stevia is perfectly positioned to capitalize on the growth of the better-for-you market."
Euromonitor forecast that stevia will have an annual growth rate of 23% globally over 2011-2016, in volume terms.
Publicly traded stevia stocks to watch include:
Sunwin Stevia International, Inc. (OTCQB: SUWN) engages in the areas of zero calorie, all natural sweeteners (Sunwin Stevia™ Extracts). As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. The Company has partnered with WILD Flavors GmbH, based in Zug, Switzerland, one of the world's leading privately-owned manufacturers of natural ingredients for the food and beverage industry. WILD's Sunwin Stevia™ brand provides beverage manufacturers one-source solutions: high-quality Stevia extracts in varying Reb Alevels plus WILD's natural Taste Optimization Technology.
S&W Seed Company (Nasdaq: SANW), founded in 1980 and headquartered in the Central Valley of California, is a leading producer of warm climate, high yield alfalfa seed varieties, including varieties that can thrive in poor, saline soils, as verified over decades of university-sponsored trials. S&W Seed also offers seed cleaning and processing at its 40-acre facility in Five Points, California and, in 2011, began the commercial launch of its California-based stevia leaf business in response to the growing global demand for the all-natural, zero calorie sweetener from the food and beverage industry.
Ingredion Incorporated (NYSE:INGR) is a leading global ingredients solutions provider specializing in nature-based sweeteners, starches and nutrition ingredients (including stevia). With customers in more than 40 countries, Ingredion, formerly Corn Products International, serves approximately 60 diverse sectors in food, beverage, brewing, pharmaceuticals and other industries
PureCircle Limited (LSE: PURE.L) is the world's leading producer of high purity stevia ingredients for the global food and beverage industry. As the driving force behind moving stevia from niche to mainstream global acceptance, we are changing the conversation around sweet for manufacturers as well as consumers
Article source: http://www.theage.com.au/lifestyle/diet-and-fitness/the-sweet-solution-20121210-2b4bv.html
Research more Agriculture stocks at Investorideas.com
http://www.investorideas.com/MSS/Arg_Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
More Sunwin info at Investorideas.com http://www.investorideas.com/CO/SUWN/
Download the IR App athttp://runningbullotc.com/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com is compensated by China Direct on behalf of SUWN, averaging four thousand two hundred per week for news publication, dissemination and profile on Invesotrideas.com , its affiliate news and email sites including ir app on Running Bull http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com